EUVIMEDOpdag EUVIMED
Multizentrische StudieKlinische StudieOpen access · CC BY 4.0

Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial

Michio Ozeki iD, Saori Endo, Shiho Yasue, Ryuta Asada, Akiko M Saito, Hiroya Hashimoto, Shigeru Ueno, Shoji Watanabe, Motoi Kato, Kyoichi Deie, Shunsuke Nosaka, Mikiko Miyasaka and 12 more

Pediatrics International · 2025-01 · 67 (1)

DOI: 10.1111/ped.70002 ↗

At a glance

Multizentrische Studie in Pediatrics International, published online on 2025-03-26. Written by Michio Ozeki and 23 co-authors. Institution: Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan. Major MEDLINE topics: Sirolimus, Vascular Malformations. Cited 8 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Agency for Medical Research and Development.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs.

Methods

In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks.

Results

Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever.

Conclusions

Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs.

Subjects

MeSH terms (MEDLINE)

SirolimusVascular MalformationsHumansMaleFemaleProspective StudiesChild, PreschoolChildTreatment OutcomeInfantAdolescentAdministration, OralQuality of Life

Author keywords

mammalian target of rapamycinsirolimus granulevascular malformationsvascular tumorsvenous malformations

Substances

Sirolimus

Authors and institutions

  • Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
  • Innovative and Clinical Research Promotion Center, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Pediatric Surgery, Tokai University School of Medicine, Hiratsuka, Japan.
  • Department of Plastic Surgery, Saitama Children's Medical Center, Saitama, Japan.

ORCID profiles: Michio Ozeki, Takanobu Maekawa, Shigehisa Fumino, Naonori Kawakubo, Akihiro Fujino

Funding

  • Japan Agency for Medical Research and Development

Cite

APA

Ozeki, M., Endo, S., Yasue, S., Asada, R., Saito, A. M., Hashimoto, H., Ueno, S., Watanabe, S., Kato, M., Deie, K., Nosaka, S., Miyasaka, M., Umezawa, A., Matsuoka, K., Kato, M., Kuroda, T., Maekawa, T., Hirakawa, S., Furukawa, T., …, & Fujino, A. (2025). Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70002

Vancouver

Ozeki M, Endo S, Yasue S, Asada R, Saito AM, Hashimoto H, et al. Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial. Pediatrics International. 2025;67(1). doi:10.1111/ped.70002

BibTeX
@article{Ozeki2025,
  author = {Ozeki, Michio and Endo, Saori and Yasue, Shiho and Asada, Ryuta and Saito, Akiko M and Hashimoto, Hiroya and Ueno, Shigeru and Watanabe, Shoji and Kato, Motoi and Deie, Kyoichi and Nosaka, Shunsuke and Miyasaka, Mikiko and Umezawa, Akihiro and Matsuoka, Kentaro and Kato, Mototoshi and Kuroda, Tatsuo and Maekawa, Takanobu and Hirakawa, Satoshi and Furukawa, Taizo and Fumino, Shigehisa and Tajiri, Tatsuro and Takemoto, Junkichi and Kawakubo, Naonori and Fujino, Akihiro},
  title = {Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial},
  journal = {Pediatrics International},
  year = {2025},
  volume = {67},
  number = {1},
  doi = {10.1111/ped.70002}
}
Start for free →